additional thanks Thanks, second call Aquestive as today July. of we this and leadership through Q&A to during afterward. and I everyone the Lauren, team joining quarter business important by through joined us and our the the are a of for in on some remarks discuss our will members John in morning, during details to the developments walk going and number be session
Yesterday, is we announced our for NDA Libervant. for This Libervant crossover now quarter. in positioned This lead positive which a for and a us the on the of path straightforward critical puts in significant clear results line study completing to asset, shareholders. is single-dose the to fourth drive milestone for filing value top our
formulations continues of has current we've the us it lacking that to diazepam. the requirements communicated approval prove FDA, for believe We that all in of and product our attributes specific met to by other
addition, you update important In other today we'll developments. two on
in QX over a to materially trend higher. and up they with the to of build the Shipments position are entry to continue We initial leadership date epilepsy continue Sympazan. market
the a deal and terms completed Second, schedule additional debt the provide we to and company. to repayment our in to order refinance reset capital
million three care crossover revenues to peak treatment post-launch. in breakthrough for us. Libervant of The news years to million into study to Let exciting years the cluster contribute seizures, material is $XXX contribution to progress four by improve context. putting about and patient of me within net represents truly a the up and start will Libervant our to potentially $XXX
patients XX% is need gel a to are medicine of application. as and only Over it with have its by Less than used be successfully rectal ability they standard-of-care a active, A it, their U.S. good they treating and when need accept. rescue the these million in where as patients form of they epilepsy need patients uncontrolled in the medication. X seizures for current
believe and that rescue shows a product potentially form looking will and patients We data safely on in preferred preferred interrupt and therapeutic alternative, Libervant differentiated medication become to results superior by This is an manage based applied, and quickly be can by comes for strong the in the consistent providers and levels clinically patients. clusters. treatment that seizure
an to our product product terms and for is of we where late-stage in bringing important Libervant market. about this are company, we're excited
Libervant's the plan terms of submission submitted with the in earlier FDA as section May year. was the submitted NDA NDA development announced accordance filing, and rolling to the In this progression of of the first in
We’ve met recently a which study, clear path to straightforward crossover for line completed primary indicate we our approval. the gives and results and the study. submission single-dose Top us objectives
the patients than Specifically, dose dose the algorithm model support gel. lower and the top will study a rectal our for confirmed is for top appropriate dosing
The the show results AED no using between the medications. also concurrent and in patients film difference gel
we a rectal the in but those gel, In of not study same patients, dose blood levels with observed Libervant. several to did patients therapeutic were the addition, in again, produce we who once respond able to
details KoL still complete, the provide presenting pool reviews are that's look a on data. weeks. the will of the the performing to we data in all Once and and coming that on over more quality timing We forward analysis statistical
to and for file planned on Libervant as of September complete portion submission in next track the our as the QX importantly, NDA to NDA in more remain We expected.
progress prescribers, continue and commercialization of payers, through primarily our the through to caregivers, are patients SYMPAZAN. approval introducing we we While progressing make process, to technology our Libervant
epilepsy in proprietary in epilepsy-related in market position capabilities Libervant. product order to us most and SYMPAZAN our treatment launched help products, was our the anticipation and complementary build-out launching as first of importantly, relationships
and In Libervant. Lennox-Gastaut SYMPAZAN syndrome, proposition both XX% from patients target there addition to prescribers greater for was than differentiated value for a suffering of overlap a
opportunity our PharmFilm for about Libervant. of value of preparation to our in eventual healthcare commercialization launch technology efforts for an of practitioners conversations the All SYMPAZAN the provide with relating direct
since within million generate has net revenue tracking in over expectations. at We in The grown of is The QX, XXX% continues volume of grow prescribing over XXX% $XX it SYMPAZAN monthly scripts with base peak and prescribers five XX% to QX. shipment line since multiple refill writing approaching those latest the believe years. with SYMPAZAN also our approximately over XX%. can end a rate
ONFI, the use This to track refills uptake favorably for we continues and liquid with Fycompa and respectively. analogs
the signed payers quarter, the by we Additional and contracts of XX% PBMs to of over of to with covered having expect the and since goal continue achieve lives our first were year. end
strategically ahead efforts will wanted to, we SYMPAZAN to growing these a only launch. contribute importantly, continue but these our and with trends. flow, accomplishing establish happy is Libervant foundation of cash what the more not We're to
Asset last in our was quarter Madryn key to mid-July upfront for additional business, with that our debt to $XX deliverable in $XX and regard, to our provides existing refinance successfully million capital. including completed The In up to $XXX up and refinancing debt others the facility. we Management million this million
$XX incremental principal This line also of was million pay-off XXXX. It reasons. payment our $XX important it us eliminating for a It Perceptive, -- number existing to capital. bullet in immediate of including million near-term a repayments, allowed allows provided an injection with of to us
March provides conditions, X-K in satisfaction based which XX, of for of the of Form on XXXX, capital filed our certain $XX now July up And deal described were and additional the between XXXX. to on million
of believe ahead these can potential position the capital of royalty need Sunovion's funds, the we expected following with its monetization revenues approval, together launch. the apomorphine We product provide our Libervant and product, in FDA
have that which market. Beyond XX% strong the performing generic the in at we film very authorized Suboxone hold key Suboxone goals, against films the launched still a is very share the risk. produce, of over of well position generic,
book strong. remained order Our
and and are and As to of from million generate between the narrowing such, and now in amending our we for million We Suboxone. XXX between $XX million XXXX. revenue range million upward $XX produce Suboxone XXX guidance expect strips
remainder this year. important contribute cash While of the a to the revenue and legacy expected source for the our continues than flow of business, represents and rate an of be higher will originally at part Suboxone
or quarter. as expect data, once Additionally, pre-IND meeting move with to a on as would the Canada, trial Aquestive-XXX on in complete possible. track I to clinical Proof quickly Concept Based and we're FDA the available, we to it the third the Phase epinephrine of continues in
the to conduct and needed In be immediately move event certain reach might that formulation work studies. data modifications performance some to our of PK we'll start Concept that goals, indicates additional to Proof
PDUFA XXth product ALS, toward November Riluzole-based continues our date. a Exservan, Finally, to also move for
U.S. seeking As the begun have of United in we are product identifying commercial partners States, and said as the potential outside previously, well. to license we have we process the the
concluded successfully for the in of epilepsy in value study us advance and the was and to This continues Libervant and track drivers. key The on establishing SYMPAZAN important us progress is on NDA we in lot to Libervant relationships has of market strategic an launch. for a we're grow filing QX. the quarter complete made
through now look Suboxone, to of to access in and company's we'll based strong the improved continue position the the on We've performance of deliver potential through activities to end year. the third the additional We these strong capital. continuing on quarter have XXXX. the current capital And of see forward and rest revenues to
debt Maxwell, financial specifics the John of I'll performance. other the and now additional turn line aspects refinancing provide around to over who'll our
